Marksans Pharma Ltd

Marksans Pharma Results Update

Marksans Pharma reported a record FY26 total income of ₹3,033.5 Crore, up 12.8% YoY. The company achieved historic highs in revenue, EBITDA, and PAT during the year.

Value

₹3,034 Cr

Marksans Pharma Earnings Call: Key Takeaways

Marksans Pharma achieved milestone FY26 performance with total income of ₹3,033 cr and record PAT of ₹420 cr. Strategy focuses on global OTC leadership and Rx expansion in Australia.

Marksans Pharma Q4 FY26 Results: Net Profit ₹149 Cr, Up 64.3% YoY

Marksans Pharma Ltd reported revenue from operations of ₹856.1 Cr (+20.8% YoY) and net profit of ₹149 Cr (+64.3% YoY) for Q4 FY26.

Key figure

Net profit ₹149 Cr · +64.3% YoY

Marksans Pharma Financial Results

Marksans Pharma reported audited FY26 financial results and recommended a ₹0.90 per share dividend. Consolidated annual revenue reached ₹2,950.94 Crore, reflecting strong operational growth.

Value

₹0.90 Cr

Marksans Pharma Employee Stock Options

Marksans Pharma granted 3,00,000 stock options at Rs.10 each to eligible employees. The grant strengthens employee retention and aligns interests with long-term shareholder value.

Value

₹0.30 Cr

Execution

Vesting period is one year; exercise period is two years from vesting.

Marksans Pharma Earnings Call: Key Takeaways

Marksans Pharma reported record Q3 FY26 revenue of ₹754cr (up 10.6% YoY) with EBITDA margins expanding to 21.3%. Strategy focuses on U.S. OTC and U.K. growth.

Marksans Pharma Board Meeting Date

Marksans Pharma scheduled a board meeting for May 26, 2026. Directors will consider FY26 audited financial results and recommend equity dividends for the year.